KalshiVérifier la disponibilitéKYC requisDonnées de résolution vérifiéesBien calibréMilieu du carnet sélectionné
Before Jul 1, 2027 · —
Chargement du carnet sélectionné…
—
Prix enregistré
Before Jul 1, 2027 89.5%En tête parmi 4 options
Before Jul 1, 2027 89.5%Qualité du marché
40 / 100
Faible qualitéVolume 24h
21,5 €
Intérêt ouvert
6 k $US
Intérêt ouvert moyenAchat / Vente
— / —
Before Jul 1, 2027Écart
—
Données du marché
Mis à jour il y a 13 minutes
14 mai 26, 02:00 UTC1 janv. 27, 15:00 UTC
Le graphique et les variations affichent les probabilités historiques enregistrées, pas le carnet sélectionné en direct.
Tendances
Ligne sélectionnée : milieu du carnet. Autres lignes : références enregistrées, éventuellement normalisées ; les variations sur 24h utilisent l’historique enregistré.
Before Oct 1, 2026Perdu
Conditions de la plateforme
Source : Kalshi
Ces conditions sont indicatives ; les opérations simulées de CoinRithm suivent leurs propres règles.
- Clôture anticipée:
- Oui
- Délai de règlement:
- 30m (indicatif)
Profondeur du marché · Before Jul 1, 2027
Chargement du carnet sélectionné…
—
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
Will the FDA approve MDMA for PTSD?
KalshiWill the FDA approve intismeran autogene (V940/mRNA-4157)?
KalshiWhen will the FDA approve Intellia Therapeutics' lonvo-z?
KalshiWill the FDA approve any psychedelic substance for medical use this year?
KalshiWhen will the FDA approve Compass Pathways' COMP360 Psilocybin?
KalshiWill the FDA approve retatrutide?
KalshiRègles
If the FDA approves CagriSema for marketing before Jan 1, 2028, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
Règlement via:Food and Drug Administration
Règles de chaque résultat
- Before Jul 1, 2027
- If the FDA approves CagriSema for marketing before Jul 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jan 1, 2028
- If the FDA approves CagriSema for marketing before Jan 1, 2028, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jan 1, 2027
- If the FDA approves CagriSema for marketing before Jan 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Oct 1, 2026
- If the FDA approves CagriSema for marketing before Oct 1, 2026, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
